Promoter Hypermethylation of ATG16L2, TFAP2A, EBF2, Calcitonin, ABL1 Kinase Domain T315I Mutation Association with Imatinib Therapy Resistance and Median Survival in CML Patients of North-East India

Promoter Hypermethylation of ATG16L2, TFAP2A, EBF2, Calcitonin, ABL1 Kinase Domain T315I Mutation Association with Imatinib Therapy Resistance and Median Survival in CML Patients of North-East India

Background and Objectives: Chronic myeloid leukemia (CML) initiation and progression is regulated by epigenetic and genetic alterations. Imatinib therapy resistance in CML patients is important clinical issue. To understand association of kinase domain mutation and promoter hypermethylation of genes...

Full description

Bibliographic Details
Main Authors: Anupam Sarma, Amal Chandra Kataki, Avdhesh Kumar Rai, Munlima Hazarika, Partha Sarathi Roy, Manoj Kalita, Manab Deka, Indranil Chattopadhyay
Format: Article
Language:English
Published: West Asia Organization for Cancer Prevention 2023-02-01
Series:Asian Pacific Journal of Cancer Care
Subjects:
chronic myeloid leukemia, t315i mutation, promoter hypermethylation, imatinib mesylate, median survival, north-east india
Online Access:http://www.waocp.com/journal/index.php/apjcc/article/view/967

Internet

http://www.waocp.com/journal/index.php/apjcc/article/view/967

Similar Items